Antiallodynic Effects of Loperamide and Fentanyl against Topical Capsaicin-Induced Allodynia in Unanesthetized Primates
- 1 October 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 311 (1) , 155-163
- https://doi.org/10.1124/jpet.104.068411
Abstract
Capsaicin produces thermal allodynia in animals and humans by acting as an agonist at vanilloid receptor subtype 1 [VR1; also known as transient receptor potential vanilloid type 1 (TRPV1)]. VR1 receptors are widely distributed in the periphery (e.g., on primary afferent neurons). These studies examined the ability of loperamide (0.1–1 mg/kg s.c.; a μ-opioid agonist that is peripherally selective after systemic administration), in preventing and reversing thermal allodynia caused by topical capsaicin (0.004 M) in rhesus monkeys, within a tail withdrawal assay (n = 4; 38°C and 42°C; normally non-noxious thermal stimuli). The effects of loperamide were compared with those of the centrally penetrating μ-agonist, fentanyl (0.0032–0.032 mg/kg s.c.). We also characterized the allodynic effects of the endogenous VR1 agonist (“endovanilloid”), N-oleoyldopamine (OLDA; 0.0013–0.004 M). In this model, loperamide and fentanyl produced dose-dependent prevention of capsaicin-induced allodynia, whereas only fentanyl produced robust reversal of ongoing allodynia. Antagonism experiments with naltrexone (0.1 mg/kg s.c.) or its analog, methylnaltrexone (0.32 mg/kg s.c.), which does not readily cross the blood-brain barrier, suggest that the antiallodynic effects of loperamide and fentanyl were predominantly mediated by peripherally and centrally located μ-receptors, respectively. Loperamide and fentanyl (1 mg/kg and 0.032 mg/kg, respectively) also prevented OLDA (0.004 M)-induced allodynia. Up to the largest dose studied, loperamide was devoid of thermal antinociceptive effects at 48°C (a noxious thermal stimulus, in the absence of capsaicin). By contrast, fentanyl (0.01–0.032 mg/kg) caused dose-dependent antinociception in this sensitive thermal antinociceptive assay (a presumed centrally mediated effect). These studies show that loperamide, acting as a peripherally selective μ-agonist after systemic administration, can prevent capsaicin-induced thermal allodynia in primates in vivo, in the absence of thermal antinociceptive effects.This publication has 40 references indexed in Scilit:
- Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic κ-opioid agonists in rhesus monkeysPsychoneuroendocrinology, 2004
- Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological ModulationThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Painful Inflammation-Induced Increase in μ-Opioid Receptor Binding and G-Protein Coupling in Primary Afferent NeuronsMolecular Pharmacology, 2003
- Peripheral opioids act as analgesics in bone cancer pain in miceNeuroReport, 2003
- μ Opioid receptors and analgesia at the site of a peripheral nerve injuryAnnals of Neurology, 2003
- The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic PainThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Gastric effects of methylnaltrexone on μ, κ and δ opioid agonists induced brainstem unitary responsesNeuropharmacology, 1999
- A model of transient hyperalgesia in the behaving monkey induced by topical application of capsaicinPAIN®, 1997
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Opioid pharmacology of the antinociceptive effects of loperamide in miceBehavioural Pharmacology, 1994